[Prevention of sudden death after myocardial infarction: should the "MADIT" strategy be generally applied? Arguments against].
The Multicenter Automatic Defibrillator Implantation Trial (MADIT) suggests that survival in patients with prior myocardial infarction, asymptomatic unsustained ventricular tachycardia and reduced left ventricular function was better among the patients who received implantable cardioverter defibrillator than that in the drug-treatment group. Nevertheless the absence of data about the efficacy and security of the conventional antiarrhythmic treatment weakness its result and clinical applicability.